SCHEMBL23027802

SCHEMBL23027802

Cc1ccc(-c2nc(CCN3C(=O)c4ccccc4C3O)cs2)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
ALDH1A1 P00352 5/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
HPGD P15428 1/20 0.54
RXFP1 Q9HBX9 1/20 0.47
PKM P14618 2/20 0.46
MAPT P10636 4/20 0.43
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
GAA P10253 1/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 2/20 0.42
TP53 P04637 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23027821 0.91 LMNA (0.54) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL23027807 0.81 LMNA (1.00) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL23027786 0.77 POLB (0.63) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL20428077 0.73 ALDH1A1 (0.60) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL23027822 0.72 LMNA (0.83) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL21771179 0.72 HPGD (0.62) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL28326301 0.71 L3MBTL1 (0.58) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL23027811 0.71 LMNA (1.00) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL23027843 0.70 PKM (0.57) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL24325822 0.70 LMNA (0.78) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11357759-B2 Composition including ADAM9 inhibitor and the use thereof CHINA MEDICAL UNIVERSITY (TW) 2022-06-14 US disclosed
US-20210052562-A1 Composition Including ADAM9 Inhibitor And The Use Thereof CHINA MEDICAL UNIVERSITY (TW) 2021-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11357759-B2 Composition including ADAM9 inhibitor and the use thereof ADAM9, ADAM8, ADAM17 LMNA 1059/4885SMN1; SMN2 2906/4885ALDH1A1 818/4885
US-20210052562-A1 Composition Including ADAM9 Inhibitor And The Use Thereof ADAM9, ADAM8, ADAM17 LMNA 1059/4885SMN1; SMN2 2906/4885ALDH1A1 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.